In children with intermediate risk of relapse of acute lymphoblastic leukemia (ALL), it is essential to identify patients in need of treatment intensification. We hypothesized that the prognosis of patients with unsatisfactory reduction of minimal residual disease (MRD) can be improved by allogeneic hematopoietic stem-cell transplantation (HSCT).
INTRODUCTION
Early molecular response to therapy as evaluated by highly sensitive measurements of minimal residual disease (MRD) has outstanding prognostic impact on survival after a diagnosis of childhood acute lymphoblastic leukemia (ALL).
1,2 Therefore, MRD has been integrated as parameter for risk group stratification in many front-line trials aiming at improvement of outcome through riskadapted treatment strategies. 3 After a relapse of ALL, the blast immunophenotype, time to relapse, and site of relapse have been established as main prognostic determinants that stratify patients into different treatment groups. [4] [5] [6] High-risk patients include those with very early isolated bone marrow relapse (within 18 months from initial diagnosis of ALL), early relapse involving the bone marrow (between 18 months after initial diagnosis and 6 months after regular completion of initial treatment), and any bone marrow relapse of T-lineage ALL (Appendix Tables A1 and A2 , online only). Because outcomes were shown to be dismal after treatment with chemotherapy only, all patients with high risk of relapse have a clear indication for allogeneic hematopoietic stem-cell transplantation (HSCT), which has resulted in a significant improvement of event-free survival (EFS) and overall survival (OS) in this group. 4, 7 In contrast, no reliable indications for HSCT were available for children in the intermediate-risk group, which constitutes the largest and clinically as well as biologically most heterogeneous risk group of children with relapsed ALL. The intermediate-risk group includes children with an early or late (Ͼ 6 months after regular completion of initial treatment) combined bone marrow relapse, a late isolated bone marrow relapse of a B-cell precursor (BCP) -ALL, and very earlyandearlyisolatedextramedullaryrelapseofeitherBCP-ALLorT-cell ALL. 6 For this intermediate-risk group, no reliable criteria for a possible benefit of HSCT has been available, leading to a restrictive policy with regard to acute and late toxicities. 4, 5, 7 After first results indicating the strong predictive value of MRD after induction of relapse treatment in childhood ALL, [8] [9] [10] our group first investigated the predictive value of postinduction MRD in the bone marrow during treatment of relapsed childhood ALL in a prospective, blinded study of intermediate-risk patients who had bone marrow involvement at the diagnosis of relapse and were uniformly treated according to the Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group (ALL-REZ BFM) P95/96 study protocol. Patients with MRD Ն 10 Ϫ3 after induction were found to have a significantly inferior prognosis compared with those with MRD less than 10
Ϫ3
.
11
After the identification of MRD as an independent and the strongest prognostic factor in this prospective, blinded study, we investigated, in the ALL-REZ BFM 2002 trial, whether the poor prognosis of the intermediate-risk group with MRD Ն 10 Ϫ3 after induction can be improvedbysystematicallocationofthesepatientstoHSCTandwhetherthe excellent prognosis of patients with MRD less than 10 Ϫ3 can be maintained with chemotherapy (and irradiation) in the absence of HSCT.
PATIENTS AND METHODS

Study Design
In ALL-REZ BFM 2002, patients with an MRD level less than 10 Ϫ3 at the end of induction therapy (week 5) were allocated to receive conventional consolidation and maintenance therapy. Allogeneic HSCT was recommended only if a matched sibling donor (MSD) was available. Patients with an MRD level Ն 10 Ϫ3 were allocated to allogeneic HSCT from either related or unrelated HLA-matched donors. The outcomes of both groups defined by MRD response were compared with historical controls derived from the predecessor trial ALL-REZ BFM P95/96.
Patients and Samples
Patients in the intermediate-risk group with morphologic bone marrow involvement at diagnosis of relapse were included in this study. Additionally, the following inclusion criteria had to be met: first relapse; treatment according to the ALL-REZ BFM 2002 protocol; achievement of morphologic remission (ie, Ͻ 5% leukemia cells) in bone marrow after the fourth treatment course; and age less than 18 years at diagnosis of relapse.
Bone marrow samples were collected at diagnosis of relapse and at the end of induction therapy (after induction course F2). The median follow-up was 4.8 years (range, 1.5 to 8.9 years). Real-time MRD measurements were performed for patients registered on ALL-REZ BFM 2002 between January 1, 2002 , and May 31, 2009 . Characteristics of the study cohort are listed in Appendix Table A3 (online only) . Checking the representativeness of the study cohort, relapse-related relevant characteristics (as used in Table 1 and Appendix Table A3) were not significantly different between the study cohort (n ϭ 208) and the total cohort (n ϭ 246).
ALL-REZ BFM 2002 was an international, cooperative, multicenter trial conducted in clinical centers in Germany, Austria, Switzerland, Czech Republic, and Canada. The MRD study cohort consists of 173 patients from Germany, 17 from Austria, six from Switzerland, seven from Czech Republic (Prague), and five from Canada (Toronto). The research protocol for assessment of MRD and the treatment protocol were approved by the local medical research ethics committees. Informed consent of patients and/or guardians and bone marrow samples were obtained according to the guidelines of the local medical research ethics committees.
Treatment Protocol
The treatment of children in the intermediate-risk group (S2) was performed as depicted in Appendix Figure A1 (online only). Induction therapy consisted of two multiagent chemotherapy courses, F1 and F2, and was identical to the previous ALL-REZ BFM P95/96 trial.
11 After induction, patients were first allocated (during the pilot phase, January 1, 2002 to July 31, 2003) and later randomly assigned (during the main phase of the study, August 1, 2003 to December 31, 2010) to receive either alternating short courses (5 to 6 days) of multiagent chemotherapy (R2/R1/R2) or a more continuous treatment element including idarubicin (Protocol II-IDA), each followed either by five additional alternating R1/R2 courses and maintenance therapy or by two R courses (R1/R2) and allogeneic HSCT depending on the postinduction MRD level. CNS-directed treatment consisted of repeated triple intrathecal chemotherapy and preventive cranial irradiation in patients with bone marrow involvement. Indication for HSCT for patients with bone marrow involvement in the intermediate-risk group (S2) was based on the MRD level after induction therapy (after F2, week 5). HLA-mismatched (Ͻ nine of 10 high-resolution-typed HLA alleles identical) HSCT donors were not recommended and only considered based on individual decisions of the treating physician.
MRD Assessment
Mononuclear cells were isolated from bone marrow samples, and DNA was extracted using the Puregene DNA-Isolation kit (Qiagen, Darmstadt, Germany). Clonal T-cell receptor ␦, ␥, and immunoglobulin heavy-and light-chain gene rearrangements were identified and sequenced as previously described.
12-15 MRD quantification of bone marrow samples after induction was performed using real-time quantitative polymerase chain reaction with germline hydrolization (TaqMan; Applied Biosystems, Foster City, CA) probes and clone-specific primers as previously described. [16] [17] [18] To be eligible for the MRD-based indication of HSCT, at least two MRD markers with a minimum quantitative range of one leukemic cell in 1,000 normal cells (10 Ϫ3 ) was required, and 10 Ϫ4 was considered as a preferable lower quantitative range. Real-time quantitative polymerase chain reaction data were analyzed according to the guidelines of the EuroMRD group (formerly the European Study Group on MRD Detection in ALL).
18
Statistical Methods
Characteristics of different groups were compared for categorical variables using the 2 or Fisher's exact test as applicable. EFS and OS were estimated using the Kaplan-Meier method; the log-rank test was used for comparison of different groups. Second relapse, therapy-related death, and secondary malignancy were considered as events for EFS calculation. The cumulative incidence of competing risks, such as cumulative incidence of subsequent relapse (CIR) and cumulative incidence of therapy-related death (CID), was assessed using the Kalbfleisch-Prentice method. Gray statistics were applied for comparison of subgroups. 19, 20 For multivariate analysis of survival probability, Cox regression analysis was performed using Wald stepwise forward testing. The likelihood ratio test was used for comparison of different models.
21 SPSS software (version 18.0.1; SPSS, Chicago, OL) and the cmsprsk package of the R statistical program (http://www.r-project.org) were used.
22 Two-sided P Ͻ .05 was considered significant.
RESULTS
Outcomes of ALL Relapse Therapy According to MRD Level After Induction
A total of 236 patients were eligible for the study. Twenty-eight patients were excluded from the analysis because of insufficient sample at diagnosis of relapse or after F2 (n ϭ 7) or because the MRD criteria were not met (n ϭ 21). In 109 patients, an MRD level of less than 10 Ϫ3 (molecular good response) after the induction therapy was achieved. These patients continued with consolidation and maintenance chemotherapy and only underwent allogeneic HSCT if an MSD was available. Within the molecular good responder group, 14% of patients (n ϭ 15) received an MSD HSCT according to the recommendations of the trial protocol, whereas 7% (n ϭ 7) received a matched unrelated donor HSCT against protocol-based recommendations (Appendix Tables A4 and A5 , online only). Ninety-nine patients had MRD levels Ն 10 Ϫ3 (molecular poor response) and were eligible for allogeneic HSCT from MSDs and matched unrelated donors. Among these, 83% (n ϭ 81) underwent HSCT. Three of these HSCTs were performed from HLA-mismatched or haploidentical donors against the protocol-based recommendation. The probability of EFS (pEFS) of patients with molecular poor response was 64% Ϯ 5% and thus no longer different from the pEFS of patients with molecular good response (70% Ϯ 5%; P ϭ .292; Fig 1A) . Similarly, in patients with molecular poor response and molecular good response, there was no longer a difference in probability of OS (pOS; 73% Ϯ 7% v 68% Ϯ 5%, respectively; P ϭ .103; Fig 1B) and in the CIR (27% Ϯ 5% v 27% Ϯ 5%, respectively; P ϭ .85; Fig 1C) . The CID in the group with molecular poor response was 9.1% Ϯ 2.9% and thus significantly higher than in the cohort with molecular good response (1.8% Ϯ 1.3%; P ϭ .022; Fig 1C) . Patients with molecular poor response who did not receive an HSCT because of lack of a suitable donor (n ϭ 17, 17%) had a pEFS of only 24% Ϯ 10%, confirming the unfavorable results of the previous ALL-REZ BFM P95/96 trial in this subgroup (Appendix Fig A2, online only) . In patients with molecular good response who received allogeneic HSCT from HLA-matched sibling or unrelated donors (n ϭ 22), pEFS was 80% Ϯ 9% (one subsequent relapse and three treatment-related deaths) and thus, overall, not significantly improved compared with the pEFS of patients who had been treated with chemotherapy or radiotherapy alone (n ϭ 83; 66% Ϯ 6%; P ϭ .45).
Impact of Therapeutic Intervention Based on MRD Level After Induction
To determine whether the use of allogeneic HSCT for all intermediate-risk patients with molecular poor response resulted in clinical benefit, we compared the outcomes of corresponding MRD groups between the current study (ALL-REZ BFM 2002) and its predecessor study (ALL-REZ BFM P95/96). Both studies used the same induction therapy before the determination of MRD levels, but MRD results had not been disclosed and patients received HSCT independently from molecular response in ALL-REZ BFM P95/96.
11 Clinical characteristics and initial treatment of the study populations were not different between both studies (Appendix Table A3 ). In line with the treatment recommendation, the proportion of patients who underwent HSCT was higher in ALL-REZ BFM 2002 than ALL-REZ BFM P95/96 (51% v 24%, respectively; P Ͻ .001). The pEFS of patients with molecular poor response improved from 18% Ϯ 7% in ALL-REZ BFM P95/96 to 64% Ϯ 5% in ALL-REZ BFM 2002 (P Ͻ .001; Fig 2A) . The CIR decreased from 59% Ϯ 9% to 27% Ϯ 5% (P Ͻ .001; Fig 2C) . Treatment-related mortality in the molecular poor responder group of ALL-REZ BFM 2002 was not higher compared with ALL-REZ BFM P95/96 (CID: 9% Ϯ 3% v 21% Ϯ 7%, respectively; P ϭ .074) despite the more frequent use of HSCT in the more recent study.
Study-specific treatment (ie, the strategy of MRD-dependent HSCT indication) and presence of the fusion gene TEL-AML1 were the only independent predictors of pEFS in a multivariate Cox regression analysis of patients with molecular poor response enrolled onto ALL-REZ BFM P95/96 and ALL-REZ BFM 2002, which included known prognostic parameters (Appendix Table A6 , online only). 
Prognosis of Early Combined Bone Marrow Relapses With Molecular Good Response
Clinical characteristics, treatment, and outcomes were not significantly different between intermediate-risk patients in the good and poor MRD risk groups of the ALL-REZ BFM 2002 cohort (Table 1) except for immunophenotype and site of relapse. Common ALL and biphenotypic ALL were significantly more frequent in the molecular good responder group (75% and 5%, respectively) compared with the poor responder group (69% and 0%, respectively), whereas pro-B ALL was more common in the molecular poor responder group (8%) compared with the good responder group (1%; P ϭ .008). The proportion of patients with a combined relapse was significantly higher in the molecular good responder group (37%) compared with the poor responder group (19%; P ϭ .005). Among molecular good responders with a combined relapse, 43% experienced relapse early. Within the molecular good response group, patients with an early combined bone marrow relapse had a significantly lower pEFS (37% Ϯ 13%) compared with patients with a late combined or isolated bone marrow relapse (76% Ϯ 5%; P ϭ .026; Fig 3A) ; this difference can be mainly attributed to a higher rate of subsequent relapse (20% Ϯ 5% v 63% Ϯ 13%, respectively; P Ͻ .001; Fig 3B) .
Confirmation of the MRD Cutoff After Induction
To confirm the MRD cutoff of 10
Ϫ3
, we investigated the outcome of intermediate-risk patients who are not recommended to receive HSCT in subsequent trials such as patients with a late relapse and MRD good response. Patients with an MRD level less than 10 Ϫ4 had a pEFS of 79% Ϯ 7.3% compared with 60% Ϯ 11% (P ϭ .119) for patients with MRD less than 10 Ϫ3 and Ն 10 Ϫ4 (Appendix Fig A3,  online only) . Therefore, the MRD cutoff of 10 Ϫ3 to determine the indication for HSCT versus chemotherapy only in intermediate-risk patients can be considered confirmed in context of ALL-REZ BFM induction therapy.
DISCUSSION
The prognostic value of MRD after induction therapy and at other time points during treatment of ALL has been demonstrated in different studies for children and adolescents. 26 Because of its superiority as a prognostic marker compared with conventional parameters, MRD has been used in many trials for risk group stratification.
27-29 However, it has not been shown to date whether outcomes are improved by a MRD-based stratification of treatment.
We found that after the introduction of an MRD-based indication of HSCT for children and adolescents with an intermediate risk of first relapse of ALL, pEFS, CIR, and pOS of molecular poor responders were no longer significantly different from those of molecular good responders and conclude that the former clearly benefitted from MRD-based indication of HSCT within the ALL-REZ BFM 2002 trial. In addition, the standardization of HSCT procedures, including HLA typing, donor selection, conditioning regimen, graft-versus-host disease prophylaxis, standards of supportive care, comprehensive and closely reviewed documentation, and serious adverse event reporting, likely contributed to improved survival by reducing transplantationrelated mortality.
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The prognostic significance of MRD and any identified cutoff level is protocol dependent and not necessarily applicable for other protocols. The recently published ALL R3 trial for treatment of children and adolescents with relapsed ALL used MRD after induction to determine the indication of HSCT in the intermediate-risk group as well. 31 In that trial, the MRD cutoff level of 10 Ϫ4 was used, because the induction regimen in ALL R3 was supposed to be more intensive than the F1/F2 induction courses of the ALL-REZ BFM P95/96 and 2002 protocols. Moreover, during induction of ALL R3, idarubicin and mitoxantrone were randomly assigned (given on days 1 and 2). pEFS was significantly better after treatment with mitoxantrone compared with idarubicin, whereas the molecular response after induction was not different. This study illustrated that MRD level after induction cannot be used as an early surrogate end point for the effect of different induction regimens on outcome. 31 We previously showed that in early and late relapse, a combined bone marrow relapse has a more favorable prognosis than an isolated bone marrow relapse. 32 Because of their intermediate prognosis, patients with an early combined relapse, therefore, were included in the intermediate-risk group (S2). In contrast, patients with early isolated bone marrow relapse were stratified into the high-risk group (S3), which because of its poor prognosis is eligible for HSCT regardless of the MRD response. We observed an unexpected excess of adverse events among patients with early combined bone marrow relapse and an MRD good response, whereas the proportion of relapses involving the CNS or testes did not significantly differ between early and late combined relapses in our ALL-REZ BFM 2002 cohort. The prognosis of patients with an early combined relapse in the context of a molecular good response was not as unfavorable as that of high-risk patients without HSCT. Consistent with our results, Coustan-Smith et al 8 observed a dismal outcome in 80% of patient (four of five patients) with ontherapy relapses with MRD good response to induction. The Children's Oncology Group found that the 12-month pEFS after a late relapse (Ն 36 months after initial diagnosis) with MRD poor response to induction (77% Ϯ 9%) is similar to that after early relapse (Ͻ 36 months) with MRD good response (67% Ϯ1 6%) and concluded that both groups as defined by time point of relapse and MRD response to induction belong to a common risk group. 10 However, neither study considered the exact relapse time point (during v after the first 18 months from initial diagnosis) and site of relapse (combined v isolated bone marrow relapse). Our results demonstrate that a molecular good response to induction treatment within a homogeneously treated population with relapsed ALL does not predict a good prognosis in all subgroups. As a result, all patients with an early combined bone marrow relapse will be eligible for well-matched allogeneic HSCT. In contrast, prognosis of patients with a late combined or a late isolated bone marrow relapse and MRD good response is remarkable and comparable to current outcome data of newly diagnosed intermediate-risk patients. 29 The investigation of the pathophysiologic involvement of extramedullary sites in early and late ALL relapses and their niches are essential for a better understanding of relapse development and treatment response.
Our results demonstrate that the poor prognosis of patients with molecular poor response can clearly be improved by systematic allocation of these patients to allogeneic HSCT. This observation establishes MRD after induction as a fully validated parameter for HSCT indication. Finally, we demonstrate that the predictive value of MRD cannot be applied to intermediate-risk patients with early combined relapse who require treatment intensification by allogeneic HSCT irrespective of MRD response.
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